EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE ...
Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The Dexcom G7 15 Day ...
Zacks Investment Research on MSN
Can Dexcom Deliver Strong Q3 Earnings on Stelo Gains and G7 Adoption?
DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported quarter, the company’s adjusted earnings per share (EPS) of 48 ...
Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...
DexCom (NASDAQ:DXCM) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a condensed view of their recent ratings, ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback